A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
Interventions: DRUG: Fluzoparib; Apatinib|DRUG: Fluzoparib|DRUG: Physician's choice chemotherapy
Sponsor: Jiangsu HengRui Medicine Co., Ltd.